- Home
- PSF vs CATX Comparison
PSF vs CATX Comparison
Compare PSF & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSF | CATX |
|---|---|---|
| Founded | 2010 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 211.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PSF | CATX |
|---|---|---|
| Price | $20.28 | $2.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.56 |
| AVG Volume (30 Days) | 25.0K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,075,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.00 | $1.60 |
| 52 Week High | $20.19 | $5.39 |
Technical Indicators
Market Signals| Indicator | PSF | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 58.67 |
| Support Level | $20.09 | $2.45 |
| Resistance Level | $20.26 | $2.90 |
| Average True Range (ATR) | 0.16 | 0.21 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 43.76 | 94.17 |
Price Performance
Historical ComparisonAbout PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.